Treace Medical Concepts, Inc.
Financials
Valuation Metrics
Treace Medical Concepts, Inc.'s Market Cap is $286M. At end of 2025 it was $156M. Ranked #2889 of 3,116 in US market (top 93%), #1298 of 1,472 on NASDAQ (top 88%), #182 of 203 in Health Care Equipment & Services (top 90%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $286M | US#2,889/3,116 Sec#182/203 |
| Revenue | $205M | US#2,543/3,116 Sec#171/203 |
| Net Income | $-60M | US—/3,116 Sec—/203 |
| Total Assets | $181M | US#2,996/3,116 Sec#190/203 |
| Net Assets | $68M | US#2,830/3,116 Sec#184/203 |
| Employees | 450 | US#2,299/3,116 Sec#159/203 |
| Value | ||
| P/B | 4.23x | US#2,182/3,116 Sec#127/203 |
| P/S | 1.40x | US#1,084/3,116 Sec#70/203 |
| FCF Yield | -8.75% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -87.86% | US#2,769/3,116 Sec#178/203 |
| ROA | -32.87% | US#2,895/3,116 Sec#189/203 |
| Op. Margin | -26.17% | US#2,599/3,116 Sec#169/203 |
| Revenue Growth | -3.95% | US#2,397/3,116 Sec#181/203 |
| Financial Health | ||
| Debt Ratio | 167.29% | US#1,607/3,116 Sec#138/203 |
| Total Debt | $73M | US#2,513/3,116 Sec#148/203 |
| FCF | $-25M | US#2,444/3,116 Sec#163/203 |
| Cash | $13M | US#2,930/3,116 Sec#196/203 |
| Current Ratio | 2.90x | US#814/3,116 Sec#80/203 |
| Performance | ||
| 1Y Return | -30.47% | US#2,470/3,116 Sec#165/203 |
| 1M Return | -0.56% | US#775/3,116 Sec#77/203 |
| From 52W High | -37.64% | US#1,942/3,116 Sec#153/203 |
| 1Y MDD | -82.16% | US#3,057/3,116 Sec#200/203 |
| Trading | ||
| Volume | 264,146 shares | US#2,289/3,116 Sec#160/203 |
| Trading Value | $1M | US#2,910/3,116 Sec#190/203 |
| Per Share | ||
| EPS | $-0.92 | US—/3,116 Sec—/203 |
| BPS | $1.04 | US#2,686/3,116 Sec#180/203 |
Company Info
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.